Trials / Recruiting
RecruitingNCT07308236
A Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants
An Open-Label, Single Dose Study to Determine the Metabolism and Excretion of [14C]E2086 in Healthy Male Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Eisai Inc. · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to determine the metabolism and excretion of \[14C\]E2086 in healthy male participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E2086 | E2086 oral capsule. |
Timeline
- Start date
- 2025-12-31
- Primary completion
- 2026-02-23
- Completion
- 2026-02-23
- First posted
- 2025-12-29
- Last updated
- 2026-03-05
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07308236. Inclusion in this directory is not an endorsement.